Compare MATX & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATX | RYTM |
|---|---|---|
| Founded | 1882 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.8B |
| IPO Year | 1994 | 2017 |
| Metric | MATX | RYTM |
|---|---|---|
| Price | $212.94 | $102.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $163.33 | $131.14 |
| AVG Volume (30 Days) | 281.9K | ★ 872.9K |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.83% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ 1.85 | N/A |
| Revenue | ★ $3,344,500,000.00 | N/A |
| Revenue This Year | $4.65 | $55.34 |
| Revenue Next Year | $4.31 | $86.06 |
| P/E Ratio | $116.70 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $86.97 | $74.50 |
| 52 Week High | $230.74 | $122.20 |
| Indicator | MATX | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 44.52 |
| Support Level | $189.60 | $98.30 |
| Resistance Level | $230.74 | $113.51 |
| Average True Range (ATR) | 7.54 | 3.77 |
| MACD | 0.27 | -1.71 |
| Stochastic Oscillator | 49.19 | 4.62 |
Matson Inc is engaged in providing ocean transportation and logistics services. The company has two reportable business segments: Ocean Transportation and Logistics. The Ocean Transportation segment provides ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, California, Okinawa, and different islands in the South Pacific. The Logistics segment offers long-haul and regional highway trucking services, warehousing and distribution services, supply chain management, and freight forwarding services. The firm generates the majority of its revenue from the Ocean Transportation segment.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.